Is HCA Healthcare Stock Underperforming the Nasdaq?

HCA Healthcare, Inc. (HCA), headquartered in Nashville, Tennessee, owns and operates hospitals and related healthcare entities. Valued at $87 billion by market cap, the company provides diagnosis, treatments, consultancy, nursing, surgeries, and other services, as well as medical education, physician resource center, and training programs. 

Companies worth $10 billion or more are generally described as “large-cap stocks,” and HCA definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the medical care facilities industry. HCA's strengths include its scale, cost leadership, and diversified portfolio. With a strong presence in high-growth states like Florida, Texas, and Tennessee, HCA leverages favorable demographics and growing healthcare demand. Its brand recognition fosters patient trust, and innovation through tech partnerships and digital health investments drives growth. HCA prioritizes talent management, positioning itself for long-term success in value-based care and telehealth trends.

Despite its notable strength, HCA slipped 27% from its 52-week high of $556.52, achieved on Mar. 12. Over the past three months, HCA stock gained 11.6%, outperforming Nasdaq Composite’s ($NASX) 1.6% dip during the same time frame.

Shares of HCA fell 13.2% on a YTD basis and dipped marginally over the past 52 weeks, underperforming NASX’s YTD gains of 13.7% and 23% returns over the last year.

To confirm the bearish trend, HCA has been trading below its 200-day moving average since late April. However, the stock has been trading above its 50-day moving average since early July, experiencing some fluctuations.

HCA’s underperformance was primarily driven by a worsening payer mix, as millions of individuals lost coverage through health insurance exchanges following the expiration of Affordable Care Act subsidies. This shift toward uninsured or underinsured patients led to sharp declines in high-margin elective inpatient and outpatient surgeries, creating a broader-than-expected drag on reimbursement rates. Although steady growth in emergent surgical cases helped cushion these volume losses, management was ultimately forced to slash its full-year EPS guidance to a range of $28.70 to $30.50. 

In the competitive arena of medical care facilities, Tenet Healthcare Corporation (THC) has taken the lead over HCA, showing resilience with a 32.3% uptick on a YTD basis and a 40.7% gain over the past 52 weeks.

Wall Street analysts are reasonably bullish on HCA’s prospects. The stock has a consensus “Moderate Buy” rating from the 25 analysts covering it, and the mean price target of $455.05 suggests a potential upside of 12% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.